enGene Holdings Inc. - ENGN
Ownership (Schedule 13D / 13G) · latest 50 filings
· Back to all files
Visible: 0
| Filed | Form | Reporting person | Percent | Shares | SEC |
|---|---|---|---|---|---|
| Aug 14, 2026 | SCHEDULE 13G/A | Perceptive Advisors LLC | 9.99% | 6,899,803 | View |
| Aug 14, 2026 | SCHEDULE 13G/A | Joseph Edelman | 9.99% | 6,899,803 | View |
| Aug 14, 2026 | SCHEDULE 13G/A | Perceptive Life Sciences Master Fund, Ltd. | 9.99% | 6,899,803 | View |
| Aug 14, 2026 | SCHEDULE 13G/A | Venrock Healthcare Capital Partners III, L.P. | 0.0% | 0 | View |
| Aug 14, 2026 | SCHEDULE 13G/A | VHCP Co-Investment Holdings III, LLC | 0.0% | 0 | View |
| Aug 14, 2026 | SCHEDULE 13G/A | Venrock Healthcare Capital Partners EG, L.P. | 0.0% | 0 | View |
| Aug 14, 2026 | SCHEDULE 13G/A | VHCP Management III, LLC | 0.0% | 0 | View |
| Aug 14, 2026 | SCHEDULE 13G/A | VHCP Management EG, LLC | 0.0% | 0 | View |
| Aug 14, 2026 | SCHEDULE 13G/A | Nimish Shah | 0.0% | 0 | View |
| Aug 14, 2026 | SCHEDULE 13G/A | Bong Y. Koh | 0.0% | 0 | View |
| Aug 14, 2026 | SCHEDULE 13G/A | Deep Track Capital, LP | 0.0% | 0 | View |
| Aug 14, 2026 | SCHEDULE 13G/A | Deep Track Biotechnology Master Fund, Ltd. | 0.0% | 0 | View |
| Aug 14, 2026 | SCHEDULE 13G/A | David Kroin | 0.0% | 0 | View |
| Aug 13, 2026 | SCHEDULE 13G/A | Invus Public Equities, L.P. | 8.2% | 5,481,984 | View |
| Aug 13, 2026 | SCHEDULE 13G/A | Invus Public Equities Advisors, LLC | 8.2% | 5,481,984 | View |
| Aug 13, 2026 | SCHEDULE 13G/A | Invus Global Management, LLC | 8.2% | 5,481,984 | View |
| Aug 13, 2026 | SCHEDULE 13G/A | Siren, L.L.C. | 8.2% | 5,481,984 | View |
| Aug 13, 2026 | SCHEDULE 13G/A | Avicenna Life Sci Master Fund LP | 1.2% | 774,678 | View |
| Aug 13, 2026 | SCHEDULE 13G/A | Avicenna Life Sci Master GP LLC | 1.2% | 774,678 | View |
| Aug 13, 2026 | SCHEDULE 13G/A | Ulys, L.L.C. | 1.2% | 774,678 | View |
| Aug 13, 2026 | SCHEDULE 13G/A | Raymond Debbane | 9.3% | 6,256,662 | View |
| Aug 12, 2026 | SCHEDULE 13G/A | Blue Owl Capital Holdings LP | 0.76% | 511,177 | View |
| Jul 22, 2026 | SCHEDULE 13G | ACORN BIOVENTURES, L.P. | 2.1% | 1,410,059 | View |
| Jul 22, 2026 | SCHEDULE 13G | ACORN CAPITAL ADVISORS GP, LLC | 2.1% | 1,410,059 | View |
| Jul 22, 2026 | SCHEDULE 13G | ACORN BIOVENTURES 2, L.P. | 2.9% | 1,947,223 | View |
| Jul 22, 2026 | SCHEDULE 13G | Acorn Capital Advisors GP 2, LLC | 2.9% | 1,947,223 | View |
| Jul 22, 2026 | SCHEDULE 13G | Anders Hove | 5.0% | 3,357,282 | View |
| May 15, 2026 | SCHEDULE 13G/A | Cormorant Asset Management, LP | 0.0% | 0 | View |
| May 15, 2026 | SCHEDULE 13G/A | Bihua Chen | 0.0% | 0 | View |
| May 14, 2026 | SCHEDULE 13G/A | BML Investment Partners, L.P. | 9.95% | 6,669,908 | View |
| May 13, 2026 | SCHEDULE 13G | BML Investment Partners, L.P. | 7.8% | 5,225,000 | View |
| May 05, 2026 | SCHEDULE 13G/A | Invus Public Equities, L.P. | 6.7% | 4,513,228 | View |
| May 05, 2026 | SCHEDULE 13G/A | Invus Public Equities Advisors, LLC | 6.7% | 4,513,228 | View |
| May 05, 2026 | SCHEDULE 13G/A | Invus Global Management, LLC | 6.7% | 4,513,228 | View |
| May 05, 2026 | SCHEDULE 13G/A | Siren, L.L.C. | 6.7% | 4,513,228 | View |
| May 05, 2026 | SCHEDULE 13G/A | Avicenna Life Sci Master Fund LP | 1.1% | 739,931 | View |
| May 05, 2026 | SCHEDULE 13G/A | Avicenna Life Sci Master GP LLC | 1.1% | 739,931 | View |
| May 05, 2026 | SCHEDULE 13G/A | Ulys, L.L.C. | 1.1% | 739,931 | View |
| May 05, 2026 | SCHEDULE 13G/A | Raymond Debbane | 7.8% | 5,253,159 | View |
Percent = "% of class represented by amount beneficially owned" for this reporting person in the filed 13D/13G.
Shares = reported beneficial ownership amount for the same row (not portfolio shares from 13F).
Amendments (/A) can repeat the same holder over time, so rows should not be summed.
Extraction is best-effort from filing text and can be missing or noisy; verify exact figures via the SEC link in each row.